<DOC>
	<DOCNO>NCT01499953</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety rivaroxaban versus fondaparinux treatment superficial vein thrombosis ( SVT ) .</brief_summary>
	<brief_title>Superficial Vein Thrombosis ( SVT ) Treated With Rivaroxaban Versus Fondaparinux</brief_title>
	<detailed_description>Evaluation efficacy safety 45 day rivaroxaban 10 mg vs. fondaparinux 2.5 mg treatment superficial vein thrombosis risk patient major VTE complication prove non-inferiority oral rivaroxaban treatment</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>acute symptomatic supragenual superficial vein thrombosis leg least one follow major risk factor VTE : age &gt; 65 year male sex history DVT/PE/SVT history cancer active cancer autoimmune disease SVT nonvaricose vein thrombus extension least 5 cm proximal thrombus end 3 cm distance saphenofemoral junction ( SFJ ) age &gt; 18 year write informed consent indication therapeutic anticoagulation acute deep vein thrombosis , acute pulmonary embolism , atrial fibrillation indication anticoagulant therapy PE DVT within last 6 month inclusion clinical sign PE without objective exclusion ( CT VQ scan , angiography ) SVT without sign thrombotic/inflammatory activity ( activity sign : diameter &gt; 4 mm , pain , redness , elevate local systemic temperature ) SVT sclerotherapy Duration symptom &gt; 3 week pretreatment 72 h therapeutic dosage oral parenteral anticoagulant pretreatment 5 day subtherapeutic oral parenteral anticoagulant indication escalate antiplatelet therapy ( monotherapy aspirin &gt; 325 g/d dual antiplatelet therapy ) SVT closer 3 cm saphenofemoral junction ( SVJ ) anticipate superficial vein surgery within 90 day anticipate thrombolytic therapy within 90 day manifest clinically relevant bleed clinically relevant bleeding last 30 day study inclusion major surgery within last 30 day inclusion ophthalmic , spinal cerebral surgery within last 90 day severe head trauma within last 90 day hemorrhagic stroke within last 12 month hereditary acquire severe hemorrhagic diathesis gastrointestinal bleeding within last 90 day require endoscopy uncontrolled arterial hypertension ( systolic &gt; 180 mm Hg , diastolic &gt; 110 mm Hg ) acute endocarditis low platelet count ( &lt; 100 x 109/l ) Prothrombin time &lt; 50 % calculated creatinine clearance &lt; 30 ml/min significant liver disease acute hepatitis , chronic active hepatitis , cirrhosis life expectancy &lt; 3 month contraindication list rivaroxaban fondaparinux woman child bear potential without safe contraception method pregnant breastfeed woman participation another trial pharmacological intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>superficial vein thrombosis</keyword>
	<keyword>thrombosis</keyword>
	<keyword>SVT</keyword>
</DOC>